Replies to post #106608 on Amarantus Bioscience Holdings Inc (AMBS)

[sumotrader]

Has a nice ring to it!

the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.

"We are very pleased that in this interim analysis with a small sample size, we were able to demonstrate a statistically significant difference between Alzheimer's disease and healthy normal subjects," said Gerald E. Commissiong, President & CEO of Amarantus. It illustrates the robustness of the LymPro assay measures.

Sorry you missed the boat

AMBS

[68-Tele]

Says overall accuracy of 80%

[sumotrader]

"Our initial target market for LymPro will be the pharmaceutical industry, for enrichment of their clinical trial enrollment population prior to undergoing the expense and waste of advanced imaging techniques for Alzheimer's biomarkers for beta amyloid and tau," said Dr. Louis Kirby, consulting neurologist and member of the Amarantus Board of Advisors who is currently overseeing the LymPro team. "Our ability to fine tune the assay to optimize for sensitivity in an Alzheimer's cohort, while retaining acceptable specificity in the non-Alzheimer's cohort is extremely valuable. We are looking forward to completing enrollment in this trial and analyzing the full dataset. Based on the positive signal we have seen today, we will continue our preparations to establish the analytical performance package to validate the LymPro in a contract laboratory to support the pharmaceutical and biotechnology industry."

Where's the bad news???



AMBS